OnKure Therapeutics, Inc.(OKUR)

Biotechnology · Boulder, CO

$2.56-0.07 (-2.66%)

Delayed quote: Oct 6, 2026, 2:30 PM EDT

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T18:32:28.364Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:32:28.364Z.

Quote observation: 2026-10-06T18:30:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 103,670,528
Total debt · period ending 2026-06-30: 926,000
Cash · period ending 2026-06-30: 166,502,000
TTM revenue · period ending 2026-06-30: 0

FMP input reference: 352cae2fe5eed9f02885becd1bbca6bb54c51239af0254a5780fc03f1b1dafbc

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

OKUR EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

OKUR Competitors' EV/Sales Ratio

OKUR

OnKure Therapeutics, Inc.

Current

Market Cap

$103.67M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BDTX

Black Diamond Therapeutics, Inc.

vs OKUR

Market Cap

$103.43M

EV/Sales Ratio

N/A

TTM Avg

1.96x

3Y Avg

1.96x

5Y Avg

1.96x

JYNT

The Joint Corp.

vs OKUR

Market Cap

$102.69M

EV/Sales Ratio

1.41x

TTM Avg

27.18x

3Y Avg

11.41x

5Y Avg

8.91x

PLYX

Polaryx Therapeutics, Inc. Common Stock

vs OKUR

Market Cap

$104.18M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANIX

Anixa Biosciences, Inc.

vs OKUR

Market Cap

$105.01M

EV/Sales Ratio

N/A

TTM Avg

501.64x

3Y Avg

356.48x

5Y Avg

292.72x

Definitive Healthcare Corp.

vs OKUR

Market Cap

$105.29M

EV/Sales Ratio

0.44x

TTM Avg

0.80x

3Y Avg

2.27x

5Y Avg

5.02x

VANI

Vivani Medical, Inc.

vs OKUR

Market Cap

$106.93M

EV/Sales Ratio

N/A

TTM Avg

147.69x

3Y Avg

74.17x

5Y Avg

63.48x

PYPD

PolyPid Ltd.

vs OKUR

Market Cap

$99.04M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CRBP

Corbus Pharmaceuticals Holdings, Inc.

vs OKUR

Market Cap

$106.81M

EV/Sales Ratio

N/A

TTM Avg

86.52x

3Y Avg

45.27x

5Y Avg

201.32x

IMUX

Immunic, Inc.

vs OKUR

Market Cap

$107.20M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
OnKure Therapeutics, Inc. (OKUR)	$103.67M	N/A	N/A	N/A	N/A
Black Diamond Therapeutics, Inc. (BDTX)vs ›	$103.43M	N/A	1.96x	1.96x	1.96x
The Joint Corp. (JYNT)vs ›	$102.69M	1.41x	27.18x	11.41x	8.91x
Polaryx Therapeutics, Inc. Common Stock (PLYX)vs ›	$104.18M	N/A	N/A	N/A	N/A
Anixa Biosciences, Inc. (ANIX)vs ›	$105.01M	N/A	501.64x	356.48x	292.72x
Definitive Healthcare Corp. (DH)vs ›	$105.29M	0.44x	0.80x	2.27x	5.02x
Vivani Medical, Inc. (VANI)vs ›	$106.93M	N/A	147.69x	74.17x	63.48x
PolyPid Ltd. (PYPD)vs ›	$99.04M	N/A	N/A	N/A	N/A
Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs ›	$106.81M	N/A	86.52x	45.27x	201.32x
Immunic, Inc. (IMUX)vs ›	$107.20M	N/A	N/A	N/A	N/A

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics